US5773025A
(en)
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
GB9325445D0
(en)
*
|
1993-12-13 |
1994-02-16 |
Cortecs Ltd |
Pharmaceutical formulations
|
US5567592A
(en)
*
|
1994-02-02 |
1996-10-22 |
Regents Of The University Of California |
Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
|
GB9405304D0
(en)
*
|
1994-03-16 |
1994-04-27 |
Scherer Ltd R P |
Delivery systems for hydrophobic drugs
|
US5430021A
(en)
*
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
DE4443175A1
(de)
*
|
1994-12-05 |
1996-06-13 |
Jenapharm Gmbh |
Neue pulsatile Arzneiform
|
US5834024A
(en)
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
ES2154806T3
(es)
*
|
1995-02-06 |
2001-04-16 |
Elan Pharma Int Ltd |
Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
|
US5716928A
(en)
*
|
1995-06-07 |
1998-02-10 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
US5665386A
(en)
*
|
1995-06-07 |
1997-09-09 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
US5916566A
(en)
*
|
1995-06-07 |
1999-06-29 |
Avmax, Inc. |
Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
|
US6024980A
(en)
*
|
1996-06-28 |
2000-02-15 |
Mcneil-Ppc, Inc. |
Multiphase soft gelatin dosage form
|
KR100321489B1
(ko)
|
1996-07-08 |
2002-10-09 |
에드워드 멘델 컴파니 인코포레이티드 |
고용량의불용성약물용서방성매트릭스
|
US6458373B1
(en)
*
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6207403B1
(en)
|
1998-01-08 |
2001-03-27 |
The Regents Of The University Of California |
Kinesin motor modulators derived from the marine sponge Adocia
|
US6056977A
(en)
*
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US20030008919A1
(en)
*
|
1999-06-03 |
2003-01-09 |
Jean-Baptiste Roullet |
Use of retinoids to treat high blood pressure and other cardiovascular disease
|
US7030155B2
(en)
*
|
1998-06-05 |
2006-04-18 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6200968B1
(en)
*
|
1998-08-06 |
2001-03-13 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
FR2782006B1
(fr)
*
|
1998-08-07 |
2002-04-19 |
Gattefosse Ets Sa |
Composition a liberation prolongee apte a former une micro-emulsion
|
US6638522B1
(en)
|
1998-12-11 |
2003-10-28 |
Pharmasolutions, Inc. |
Microemulsion concentrate composition of cyclosporin
|
US6057289A
(en)
*
|
1999-04-30 |
2000-05-02 |
Pharmasolutions, Inc. |
Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
|
US20020132001A1
(en)
*
|
2000-05-11 |
2002-09-19 |
Garthwaite Susan M. |
Aldosterone antagonist composition for release during aldosterone acrophase
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
ATE419840T1
(de)
|
2002-04-09 |
2009-01-15 |
Flamel Tech Sa |
Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US20040077621A1
(en)
*
|
2002-08-08 |
2004-04-22 |
Academia Sinica |
Antioxidants
|
CA2515544A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Kemia Inc. |
Compounds for the treatment of viral infection
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
CN1929827A
(zh)
*
|
2004-01-14 |
2007-03-14 |
拉维法姆实验室股份有限公司 |
包含至少一种脂肪酸的用于二氢吡啶类钙拮抗剂的经皮递送装置
|
JP2007522203A
(ja)
*
|
2004-02-11 |
2007-08-09 |
アスファーマ・リミテッド |
時間療法用組成物とそれらの使用方法
|
EP1766389A4
(en)
|
2004-05-12 |
2008-08-27 |
Inst Medical W & E Hall |
CELL ISOLATION PROCEDURE
|
US8648045B2
(en)
|
2005-03-10 |
2014-02-11 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
VDAC1 compositions and methods of use thereof for regulating apoptosis
|
US8119601B2
(en)
*
|
2005-03-10 |
2012-02-21 |
Ben-Gurion University Of The Negev Research And Development Authority Ltd. |
Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
|
MX2007013430A
(es)
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
CN101248177B
(zh)
|
2005-06-24 |
2012-09-05 |
沃尔特及伊莱萨霍尔医学研究院 |
治疗性促凋亡bh3样分子和用于产生和/或选择它的方法
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
AU2007207341B2
(en)
|
2006-01-20 |
2012-05-10 |
Women's & Children's Health Research Institute Incorporated |
Method of treatment, prophylaxis and diagnosis of pathologies of the bone
|
EP2004680B1
(en)
*
|
2006-04-06 |
2017-06-21 |
Ben-Gurion University Of The Negev |
N-terminal vdac variants and uses thereof
|
WO2007123153A1
(ja)
*
|
2006-04-19 |
2007-11-01 |
Ono Pharmaceutical Co., Ltd. |
経口投与用カプセル
|
MY153288A
(en)
*
|
2006-06-28 |
2015-01-29 |
Hovid Berhad |
An effective pharmaceutical carrier for poorly bioavailable drugs
|
JP5300477B2
(ja)
*
|
2006-08-01 |
2013-09-25 |
大塚製薬株式会社 |
薬理活性物質の吸収性が改善された医薬組成物
|
EP2086512A2
(en)
*
|
2006-10-27 |
2009-08-12 |
Janssen Pharmaceutica N.V. |
Dry granulated pharmaceutical compositions and methods for producing same
|
JP2010530895A
(ja)
*
|
2007-06-21 |
2010-09-16 |
アンジェリカ セラピューティックス,インク. |
修飾毒素
|
EP2537529B1
(en)
|
2007-08-02 |
2018-10-17 |
Gilead Biologics, Inc. |
Loxl2 inhibitory antibodies and uses thereof
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
DK2682400T5
(da)
*
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
|
EP2954932B1
(en)
*
|
2007-10-03 |
2018-09-19 |
WisTa Laboratories Ltd. |
Therapeutic use of diaminophenothiazines
|
WO2009110944A1
(en)
|
2008-02-29 |
2009-09-11 |
Angelica Therapeutics, Inc. |
Modified toxins
|
JP5716212B2
(ja)
*
|
2008-05-12 |
2015-05-13 |
キャプシュゲル・ベルジウム・エヌ・ヴィ |
空気ベントを有する改良されたカプセル
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
ES2657497T3
(es)
|
2009-08-17 |
2018-03-05 |
Tracon Pharmaceuticals, Inc. |
Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF
|
ES2363965B1
(es)
*
|
2009-11-20 |
2013-01-24 |
Gp Pharm S.A. |
Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US9249189B2
(en)
|
2010-01-18 |
2016-02-02 |
Albany Medical College |
Alpha-fetoprotein “ring and tail” peptides
|
PE20131376A1
(es)
|
2010-08-27 |
2013-11-25 |
Gilead Biologics Inc |
Anticuerpos para metaloproteinasa-9 de matriz
|
ES2564358T3
(es)
|
2010-10-15 |
2016-03-22 |
The Trustees Of Columbia University In The City Of New York |
Genes relacionados con la obesidad y sus proteínas y usos de los mismos
|
EP2701725A1
(en)
|
2011-04-29 |
2014-03-05 |
Kinemed, Inc. |
Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
|
WO2013049749A2
(en)
|
2011-09-29 |
2013-04-04 |
Plx Pharma Inc. |
pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
|
US9550836B2
(en)
|
2012-02-29 |
2017-01-24 |
Gilead Biologics, Inc. |
Method of detecting human matrix metalloproteinase 9 using antibodies
|
SG10201610788VA
(en)
|
2012-02-29 |
2017-03-30 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
WO2013128453A1
(en)
|
2012-03-01 |
2013-09-06 |
Yeda Research And Development Co. Ltd. |
Regeneration of islet beta cells by hsp60 derived peptides
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
TW201406707A
(zh)
|
2012-05-04 |
2014-02-16 |
Acucela Inc |
用以治療糖尿病性視網膜病變及其他眼部疾病之方法
|
US10441636B2
(en)
|
2012-07-20 |
2019-10-15 |
La Trobe University |
Method of diagnosis and treatment
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
WO2014152776A1
(en)
|
2013-03-14 |
2014-09-25 |
Uab Research Foundation |
Apolipoprotein mimetics and uses thereof
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
NZ631098A
(en)
|
2013-03-15 |
2016-09-30 |
Intrinsic Lifesciences Llc |
Anti-hepcidin antibodies and uses thereof
|
JP6549554B2
(ja)
|
2013-03-15 |
2019-07-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
コレステロール流出を刺激する、減少した毒性を有するペプチド
|
EP3024844B1
(en)
|
2013-07-25 |
2018-09-12 |
The National Institute for Biotechnology in the Negev Ltd. |
Short peptides derived from vdac1, compositions and methods of use thereof
|
EP3083672A1
(en)
|
2013-12-20 |
2016-10-26 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Pro-angiogenic peptides and peptide conjugates
|
TW201544511A
(zh)
|
2014-02-27 |
2015-12-01 |
Gilead Sciences Inc |
針對基質金屬蛋白酶9之抗體及其使用方法
|
SG11201609522TA
(en)
|
2014-06-11 |
2016-12-29 |
Gilead Sciences Inc |
Methods for treating cardiovascular diseases
|
US10793614B2
(en)
|
2014-07-17 |
2020-10-06 |
Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. |
Antagonists of fish reproduction
|
CA2954607C
(en)
|
2014-07-17 |
2023-07-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antagonists of neurokinin b in fish reproduction
|
WO2016018665A1
(en)
|
2014-07-31 |
2016-02-04 |
Uab Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
US20160074473A1
(en)
|
2014-07-31 |
2016-03-17 |
Kinemed, Inc. |
Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
|
CA2961917A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
SI3307322T1
(sl)
|
2015-09-04 |
2021-08-31 |
Primatope Therapeutics Inc. |
Humanizirana protitelesa proti CD40 in njihove uporabe
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
CA3003294A1
(en)
|
2015-10-27 |
2017-05-04 |
The University Of Queensland |
Modified epha4 and uses thereof
|
US11034739B2
(en)
|
2015-11-13 |
2021-06-15 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada |
Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
WO2017177179A1
(en)
|
2016-04-08 |
2017-10-12 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
CA3051897A1
(en)
|
2017-01-30 |
2018-08-02 |
Hudson Institute of Medical Research |
A method of treatment
|
WO2018213803A1
(en)
|
2017-05-19 |
2018-11-22 |
Neon Therapeutics, Inc. |
Immunogenic neoantigen identification
|
KR102484433B1
(ko)
|
2017-11-08 |
2023-01-03 |
바이오엔테크 유에스 인크. |
T 세포 제조 조성물 및 방법
|
WO2021195319A1
(en)
*
|
2020-03-26 |
2021-09-30 |
Plx Opco Inc. |
PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME
|
IL300564A
(en)
|
2020-08-13 |
2023-04-01 |
Biontech Us Inc |
Preparations and methods for the production of T cells
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス,インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|